Drugs / SYHX2005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05609019 | Dec 2022 → Dec 2024 | cancer | CSPC Ouyi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-26 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE FGFR4 INHIBITOR "SYHX2005" OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-26 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE FGFR4 INHIBITOR "SYHX2005" OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYHX2005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05609019 ↗ |
| Route | Oral | “Take orally.” NCT05609019 ↗ |